Cellares and Cabaletta Bio Advance CAR T Manufacturing Cellares and Cabaletta Bio successfully automated the production of rese-cel, a CAR T therapy for autoimmune diseases, using the Cell Shuttle platform. This innovation promises cost reduction, scalability, and expedited global rollout, positioning Cabaletta Bio for broader patient access and transformative treatments.5